Ginkgo Bioworks Holdings, Inc. Class A (DNA)

Ginkgo Bioworks' stock has experienced significant volatility and downward pressure in the past six months. On November 8, 2025, the stock plunged 23.54% after reporting a 56% year-over-year revenue drop in Q3 2025 due to the termination of a major customer deal. On October 31, 2025, Ginkgo announced the extension of a multi-year strategic partnership with Bayer for agricultural bio-solutions. In December 2025 and January 2026, the company announced several collaborations and participations, including partnerships with PNNL, Deep Origin, Agricen, and Carnegie-Mellon University, and participation in the 44th Annual J.P. Morgan Healthcare Conference. On February 5, 2026, Ginkgo Bioworks announced a collaboration with OpenAI, designing an AI system that reduced costs in cell-free protein synthesis by 40%, resulting in a mild positive market reaction.

Ginkgo Bioworks' business model does not inherently suggest strong seasonal demand patterns for its core offerings. Demand for its cell engineering solutions is driven by research and development cycles, industry trends, and specific project timelines. However, partnerships focused on agricultural bio-solutions might see demand influenced by agricultural cycles, and biosecurity programs could see increased focus based on outbreak patterns or public health concerns.

Ginkgo Bioworks is a biotechnology company specializing in cell programming, offering a platform for various biological applications across diverse markets. The company operates in two segments: Cell Engineering and Biosecurity. Ginkgo provides cell engineering research and development solutions, including tools for engineering organisms and developing derived products, with a goal for its tools business to generate 80% of its revenue by 2030. Through its Canopy and Horizon platforms, Ginkgo offers biomonitoring and bioinformatics support services, aiding in detecting and monitoring biothreats.

Ginkgo Bioworks is headquartered in Boston, Massachusetts, and operates primarily in the United States. As of 2021, it occupied significant facilities in Boston and Cambridge, Massachusetts. The company has also expanded its laboratory and foundry facilities in the United States and Europe.

Ginkgo Bioworks' brand reputation has been influenced by its financial performance and strategic partnerships. The company has faced skepticism from analysts due to its revenue drop in Q3 2025 and challenges in achieving profitability, with a "Reduce" consensus rating. However, partnerships with Bayer, Agricen, Carnegie-Mellon University, and Deep Origin, along with AI advancements through collaboration with OpenAI, have positively impacted its reputation.

Ginkgo Bioworks has a mixed ownership structure, with approximately 33.47% of the stock owned by institutional investors, 0.99% by insiders, and 65.54% by public companies and individual investors. Major institutional owners include Viking Global Investors Lp, BlackRock, Inc., and The Vanguard Group, Inc.